Anixa Biosciences' (ANIX) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Get Rating) in a research note published on Wednesday morning, Marketbeat.com reports. They currently have a $9.00 target price on the stock, up from their previous target price of $8.00. Chardan Capital also issued estimates for Anixa Biosciences’ FY2024 earnings at $4.61 […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,America ,Anixa Biosciences ,Geode Capital Management ,America Corp ,Cambridge Investment Research Advisors Inc ,Ci Private Wealth ,Anixa Biosciences Inc ,Nations Financial Group Inc ,Anixa Biosciences Company Profile ,Chardan Capital ,Get Rating ,Anixa Bioscience ,Capital Management ,Investment Research Advisors ,Nations Financial Group ,Cancer Vaccines ,Anti Viral Therapeutics ,Cancer Diagnostics ,Anixa Biosciences Daily ,Nasdaq Anix ,Sanix ,Medical ,Reiterated Rating ,